<DOC>
	<DOC>NCT00504270</DOC>
	<brief_summary>This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is &lt;3 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>adult patients, 1870 years of age; medically stable, moderate to severe chronic plaque psoriasis. any skin condition which may interfere with evaluation of the effect of study medication on plaque lesions; confounding or concomitant condition or treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>